• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cytodyn Inc (OP: CYDY )

    0.1246 -0.0024 (-1.89%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cytodyn Inc

    < Previous 1 2 3 4 Next >
    CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
    From CytoDyn Inc.
    Via GlobeNewswire
    September 2024 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Engages Leading CRO For Phase II Inflammation Trial
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Settlement with Amarex Clinical Research LLC
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn to Host Webcast to Provide Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    May 2024 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces FDA Has Lifted Clinical Hold
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Webcast to Provide Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
    From CytoDyn Inc.
    Via GlobeNewswire
    November 2023 Letter to Shareholders
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Company Updates and Investment Community Update Webcast
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces President Takes Medical Leave of Absence
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn to Hold Webcast to Provide a Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
    On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate... 
    Via Benzinga
    CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
    From CytoDyn Inc.
    Via GlobeNewswire
    OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
    The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
    Via Benzinga
    CytoDyn to Host R&D Update on Wednesday, December 7, 2022
    From CytoDyn Inc.
    Via GlobeNewswire
    CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
    From CytoDyn Inc.
    Via GlobeNewswire
    Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
    The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. 
    Via Benzinga
    CytoDyn Announces Appointment of Additional Directors with Industry Experience
    From CytoDyn Inc.
    Via GlobeNewswire
    OTC Markets' Most Active Securities Sees A Shake-up In July
    July gave world markets a breather from 2022’s poor financial conditions. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.